Legal & General Group’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,131
| Closed | -$18.6K | – | 3462 |
|
|
2025
Q2 | $18.6K | Sell |
4,131
-4,444
| -52% | -$20K | ﹤0.01% | 3038 |
|
|
2025
Q1 | $38K | Sell |
8,575
-26,367
| -75% | -$153K | ﹤0.01% | 2763 |
|
|
2024
Q4 | $274K | Buy |
34,942
+1,138
| +3% | +$13.9K | ﹤0.01% | 2622 |
|
|
2024
Q3 | $445K | Buy |
33,804
+1,114
| +3% | +$14.1K | ﹤0.01% | 2505 |
|
|
2024
Q2 | $395K | Buy |
32,690
+29,379
| +887% | +$397K | ﹤0.01% | 2496 |
|
|
2024
Q1 | $53.8K | Sell |
3,311
-359
| -10% | -$4.84K | ﹤0.01% | 2771 |
|
|
2023
Q4 | $25.1K | Buy |
3,670
+299
| +9% | +$1.73K | ﹤0.01% | 2943 |
|
|
2023
Q3 | $18.4K | Sell |
3,371
-550
| -14% | -$3.2K | ﹤0.01% | 3068 |
|
|
2023
Q2 | $26.6K | Sell |
3,921
-509
| -11% | -$3.81K | ﹤0.01% | 2988 |
|
|
2023
Q1 | $22.2K | Sell |
4,430
-11,045
| -71% | -$45.1K | ﹤0.01% | 3040 |
|
|
2022
Q4 | $75.5K | Hold |
15,475
| – | – | ﹤0.01% | 2875 |
|
|
2022
Q3 | $223K | Sell |
15,475
-5,993
| -28% | -$99.2K | ﹤0.01% | 2583 |
|
|
2022
Q2 | $325K | Buy |
21,468
+11,469
| +115% | +$134K | ﹤0.01% | 2463 |
|
|
2022
Q1 | $119K | Hold |
9,999
| – | – | ﹤0.01% | 2826 |
|
|
2021
Q4 | $162K | Buy |
9,999
+85
| +0.9% | +$1.82K | ﹤0.01% | 2793 |
|
|
2021
Q3 | $282K | Buy |
9,914
+5,083
| +105% | +$160K | ﹤0.01% | 2580 |
|
|
2021
Q2 | $163K | Buy |
4,831
+303
| +7% | +$9.73K | ﹤0.01% | 2591 |
|
|
2021
Q1 | $137K | Buy |
4,528
+227
| +5% | +$9.31K | ﹤0.01% | 2531 |
|
|
2020
Q4 | $212K | Sell |
4,301
-41
| -0.9% | -$1.9K | ﹤0.01% | 2409 |
|
|
2020
Q3 | $166K | Sell |
4,342
-1,317
| -23% | -$52.4K | ﹤0.01% | 2390 |
|
|
2020
Q2 | $244K | Buy |
5,659
+1,137
| +25% | +$43K | ﹤0.01% | 2323 |
|
|
2020
Q1 | $118K | Sell |
4,522
-1,077
| -19% | -$31.3K | ﹤0.01% | 2369 |
|
|
2019
Q4 | $175K | Buy |
5,599
+2,207
| +65% | +$65.3K | ﹤0.01% | 2427 |
|
|
2019
Q3 | $88K | Hold |
3,392
| – | – | ﹤0.01% | 2564 |
|
|
2019
Q2 | $78K | Buy |
3,392
+2,318
| +216% | +$53.2K | ﹤0.01% | 2616 |
|
|
2019
Q1 | $28K | Hold |
1,074
| – | – | ﹤0.01% | 2970 |
|
|
2018
Q4 | $22K | Buy |
+1,074
| New | +$24.7K | ﹤0.01% | 3043 |
|
Other funds holding YMAB
Legal & General Group's YMAB Position: Q3 2025 in Review
Legal & General Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 4,131 shares — an estimated $18.6K sold.
Legal & General Group first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $445K in Q3 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Legal & General Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Legal & General Group sold 4,131 Y-mAbs Therapeutics shares in Q3 2025, an estimated $18.6K.
- Legal & General Group first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
- Legal & General Group's Y-mAbs Therapeutics position peaked at $445K in Q3 2024.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Legal & General Group's 13F filing for Q3 2025, filed 13 Nov 2025.